A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin - Kowalski, M; Guindon, J; Brazas, L (J Urol, 2012)
et al.